News Contact Us Careers Get E-Mail alerts Search

ADMA Biologics, Inc.

  • Home
  • About Us
    • About ADMA Biologics
    • What We Do
    • Who We Are
      • Senior Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Compliance
  • Our Products
    • Products Overview
    • About Primary Immunodeficiency Disease (PI)
    • ASCENIV™
    • BIVIGAM®
    • Nabi-HB®
  • Our Pipeline
  • Immunotechnology
  • Plasma & IVIG
  • Medical Affairs
    • Medical Affairs Overview
    • Publications
  • Investors
    • Overview
    • Press Releases
      • Email Alerts
    • Company Info
      • Profile
      • Presentation
      • Management Team
      • Contacts
      • FAQ
    • Analyst Coverage
    • Events & Webcasts
    • Financial Info
      • Balance Sheets
      • Income Statement
      • Cash Flow
      • Financial Results
      • Annual Reports
    • Stock Info
      • Stock Data & Quote
      • Charts
      • Historical Data
    • SEC Filings
      • SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Board of Directors
      • Board Committees
      • Documents
  • News
  • Contact Us
  • Careers
  • Get E-Mail alerts
  • Search

You are now leaving www.admabiologics.com

The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?

Yes No

Section 16 Filings

Investors

Investors

  • Overview
  • Press Releases
    • Email Alerts
  • Company Info
    • Profile
    • Presentation
    • Management Team
    • Contacts
    • FAQ
  • Analyst Coverage
  • Events & Webcasts
  • Financial Info
    • Balance Sheets
    • Income Statement
    • Cash Flow
    • Financial Results
    • Annual Reports
  • Stock Info
    • Stock Data & Quote
    • Charts
    • Historical Data
  • SEC Filings
    • SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Documents
  • home Home
  • Investors
  • SEC Filings
  • Section 16 Filings
  • SEC Filings

  • SEC Filings
  • Annual Reports
  • Quarterly Reports
  • Section 16 Filings
Date Form Description PDF XBRL Pages
06/11/18 4 Statement of changes in beneficial ownership of securities PDF 2
06/11/18 4 Statement of changes in beneficial ownership of securities PDF 2
06/11/18 4 Statement of changes in beneficial ownership of securities PDF 2
06/11/18 4 Statement of changes in beneficial ownership of securities PDF 2
05/16/18 4 Statement of changes in beneficial ownership of securities PDF 2
02/13/18 4 Statement of changes in beneficial ownership of securities PDF 1
02/13/18 4 Statement of changes in beneficial ownership of securities PDF 1
02/13/18 4 Statement of changes in beneficial ownership of securities PDF 1
11/16/17 4/A Statement of changes in beneficial ownership of securities PDF 2
11/15/17 3 Initial statement of beneficial ownership of securities PDF 2
RSS
  • Previous
  • 1…
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • …24
  • Next
About Us Our Products Our Pipeline Inmunotechnology Plasma & IVIG Medical Affairs Investors Privacy Policy Disclaimer Sitemap Contact Us Connect with Us Email Alerts RSS

© Copyright 2022 ADMA Biologics, Inc.
Ramsey, NJ Offices 201-478-5552
Boca Raton, FL Offices 561-989-5800
info@admabio.com

Best places to work
Bio NJ

2020 Innovator Award

50 fastest companies
2019 Fast 500 Deloitte
Bio Florida

Named 2019 Company of the Year